gimli
AUROPHARMA stock analysis context
AUROBINDO PHARMA Stock Context for AI Screening
AUROBINDO PHARMA LTD is a large-cap stock in Healthcare. This page summarizes key screening signals for AUROBINDO PHARMA, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.
Ask Gimli about AUROPHARMAPrice
₹1,463.50
1M return
+2.98%
3M return
+26.29%
Market cap
₹84,206.55 cr
PE
24.17
ROE
+11.15%
RSI
52.91
Turnover
₹444.73 cr
Why it can matter in screens
- Momentum: AUROPHARMA is above 50DMA, above 200DMA; RSI is 52.91.
- Returns: 1M +2.98%, 3M +26.29%, 6M +21.36%.
- Liquidity: latest turnover is ₹444.73 cr.
- Valuation: PE 24.17, PB n/a, ROE +11.15%, ROCE +14.18%.
- Growth: 3Y sales CAGR +10.32%, 3Y profit CAGR +9.59%.
Try these prompts
- Analyze AUROBINDO PHARMA with valuation, momentum and industry peers
- Compare AUROPHARMA with other Healthcare stocks
- Show large-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View large-cap stocks
- Find stocks above 50DMA
- Compare AUROPHARMA with other Healthcare stocks
Data snapshot: 2026-05-22. Not investment advice.